Guggenheim Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)

Guggenheim reiterated their buy rating on shares of uniQure (NASDAQ:QURE) in a research note released on Wednesday,Benzinga reports.

Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. The Goldman Sachs Group cut their target price on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $20.00 to $52.00 in a research report on Tuesday. StockNews.com raised shares of uniQure to a “sell” rating in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of uniQure in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average price target of $32.14.

uniQure Stock Up 2.3 %

NASDAQ QURE opened at $15.40 on Wednesday. The stock has a 50 day moving average price of $6.85 and a 200-day moving average price of $6.28. uniQure has a one year low of $3.73 and a one year high of $17.39. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market capitalization of $750.60 million, a P/E ratio of -3.10 and a beta of 0.89.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, equities analysts predict that uniQure will post -3.81 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after acquiring an additional 109,740 shares in the last quarter. SG Americas Securities LLC purchased a new position in uniQure during the 2nd quarter valued at about $79,000. Clear Harbor Asset Management LLC increased its position in uniQure by 35.2% during the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 12,500 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of uniQure in the 2nd quarter valued at about $815,000. Finally, Privium Fund Management B.V. lifted its position in shares of uniQure by 10.6% in the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock worth $2,869,000 after purchasing an additional 61,501 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.